Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
2011
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
2012
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
2012
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
2008
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
2010
ESUR prostate MR guidelines 2012
2012 Standout
Molecular imaging in drug development
2008 Standout
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
2014
Idiopathic pulmonary fibrosis
2017 Standout
Medical imaging in pharmaceutical clinical trials: what radiologists should know
2005
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Cancer to bone: a fatal attraction
2011 Standout
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
2006
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
2010
Value of Targeted Prostate Biopsy Using Magnetic Resonance–Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen
2013
Ovarian cancer
2014 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Phaeochromocytoma
2005 Standout
Prostate Cancer Localization Using Multiparametric MR Imaging: Comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert Scales
2013
Measurements of T1‐relaxation in ex vivo prostate tissue at 132 μT
2012 StandoutNobel
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging
2011
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
The tumor microenvironment
2020 Standout
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases
2010
Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
2007
Lung cancer: current therapies and new targeted treatments
2016 Standout
The WU-Minn Human Connectome Project: An overview
2013 Standout
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
von Hippel-Lindau disease
2003 Standout
Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis
2011
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
PET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A″‐DTPA‐bevacizumab
2010
Translation of new cancer treatments from pet dogs to humans
2008 Standout
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
2010
Malignant Gliomas in Adults
2008 Standout
Management of hypertension in angiogenesis inhibitor-treated patients
2009
Angiogenesis in brain tumours
2007
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
ACR Appropriateness Criteria Prostate Cancer—Pretreatment Detection, Staging, and Surveillance
2013
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
2014
An integrative model for neuronal activity-induced signal changes for gradient and spin echo functional imaging
2009
Adverse effects of anticancer agents that target the VEGF pathway
2009
Biomarkers of response and resistance to antiangiogenic therapy
2009
Primary brain tumours in adults
2012 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives
2008
Quantitative Evaluation of Computed High b Value Diffusion-Weighted Magnetic Resonance Imaging of the Prostate
2013
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
2015 Standout
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
CEREBRAL ARTERIOVENOUS MALFORMATIONS
2007
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
Pulmonary Arterial Hypertension: Diagnosis with Fast Perfusion MR Imaging and High-Spatial-Resolution MR Angiography—Preliminary Experience
2005
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound–Guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective
2013
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Fibroblasts in the Tumor Microenvironment
2020
Tumor Angiogenesis
2008 Standout
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
2019
An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition
2011
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?
2012
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors
2007
Cerebral Arteriovenous Malformations: Comparison of Novel Magnetic Resonance Angiographic Techniques and Conventional Catheter Angiography
2001
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019 Standout
Comparison of Interreader Reproducibility of the Prostate Imaging Reporting and Data System and Likert Scales for Evaluation of Multiparametric Prostate MRI
2013
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
2010
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
2009
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
2012 Standout
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
2013
CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas)
2004
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
2007
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
2007
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
2007
Diagnosis and Treatment of Venous Malformations. Consensus Document of the International Union of Phlebology (IUP): updated 2013.
2009
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
2019 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation
2013
Current Classification and Terminology of Pediatric Vascular Anomalies
2013
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease
2019
Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies
2015 Standout
Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer
2015 Standout
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
2014 Standout
Works of Ralph Strecker being referenced
Assessment of vascular remodeling under antiangiogenic therapy using DCE‐MRI and vessel size imaging
2009
Vessel size imaging in humans
2005
Dynamic contrast enhancement of paragangliomas of the head and neck: evaluation with time-resolved 2D MR projection angiography
2002
Time‐resolved projection angiography after bolus injection of contrast agent
1997
Parkes Weber or Klippel-Trenaunay syndrome? Non-invasive diagnosis with MR projection angiography
2004
Areas Suspicious for Prostate Cancer: MR–guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding—Multiparametric MR Imaging for Detection and Biopsy Planning
2011
DCE-MRI in clinical trials: data acquisition techniques and analysis methods
2003
Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study
2007
Assessment of Pulmonary Perfusion With Ultrafast Projection Magnetic Resonance Angiography in Comparison With Lung Perfusion Scintigraphy in Patients With Malignant Stenosis
2002
Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases
2004
Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors
2005
A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients
2005
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
2009
Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases
2004
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
2007